Business Context and Reporting Period
Company: Foresight Autonomous Holdings Ltd. (FRSX)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: An Israeli technology company developing advanced 3D perception systems (stereoscopic vision) and cellular-based Vehicle-to-Everything (V2X) applications. Operations are conducted through subsidiaries Foresight Automotive (3D vision), Foresight Changzhou (China operations), and Eye-Net Mobile (V2X solutions).
Accounting Basis: U.S. GAAP.
Going Concern: The financial statements include an explanatory paragraph regarding substantial doubt about the Company's ability to continue as a going concern due to accumulated losses and dependence on external financing.
Key Financial Metrics
| Metric (USD in thousands) | 2025 | 2024 |
|---|---|---|
| Revenues | $398 | $436 |
| Gross Profit | $258 | $264 |
| Operating Loss | $(12,181) | $(12,676) |
| Net Loss | $(12,103) | $(11,138) |
| Cash and Cash Equivalents (End of Period) | $6,236 | $7,082 |
| Accumulated Deficit | $(142,931) | $(131,028) |
| Research & Development Expenses | $8,629 | $9,143 |
| Capital Expenditures | $25 | $62 |
Liquidity: As of December 31, 2025, the Company held approximately $6.3 million in cash and cash equivalents. Management estimates these funds are sufficient to support operations through August 2026.
Material Changes vs. Prior Period
- Revenue Decline: Revenues decreased by 8.7% to $398,000, primarily due to lower POC project completions compared to 2024, despite commercialization efforts with Elbit ($162,000).
- Net Loss Increase: Net loss increased by 8.7% to $12.1 million. This was driven by a significant reduction in financial income (from $1.5 million in 2024 to $78,000 in 2025) following the sale of Rail Vision shares in 2024, which provided a one-time gain.
- Expense Reductions: Operating expenses decreased slightly. R&D expenses dropped 5.6% due to reduced payroll and subcontracted work. General and Administrative expenses decreased 2.4%.
- Capital Structure: The Company executed a 1-for-7 reverse share split in August 2025. In 2025, the Company raised approximately $9.5 million in net proceeds through equity transactions, including sales of ADSs and investments in the Eye-Net Mobile subsidiary.
Guidance, Outlook, and Risks
Outlook: The Company expects to continue incurring significant losses until products are successfully commercialized. Revenue growth is anticipated from upcoming serial production agreements with partners in rail transit (StreamRail), drones (Big Bang), and agriculture (KONEC/GINT), with initial sales expected in 2026.
Material Risks:
- Going Concern: Substantial doubt exists regarding the ability to continue operations without additional financing. Failure to raise capital could force a curtailment of R&D or operations.
- Geopolitical Instability: Headquarters and operations are in Israel. Ongoing conflicts in the region (Israel, Iran, Hezbollah) pose risks to operations, personnel, and supply chains, though no material adverse effect has been reported to date.
- Commercialization: The Company has not yet generated significant recurring revenue from product sales. Success depends on completing development and securing volume production contracts.
- Intellectual Property: Reliance on patents and trade secrets; risks of infringement claims or inability to enforce rights.
- Regulatory Compliance: Subject to Nasdaq listing requirements (minimum bid price) and Israeli government grants (IIA) which impose royalty obligations and restrictions on technology transfer.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $6.3 million cash balance to fund operations through the projected August 2026 date, considering the high burn rate (~$12M annual loss).
- Revenue Recognition: Confirm the nature of the $398k revenue (primarily POC and development fees) versus recurring product sales to assess commercialization progress.
- Financing Terms: Review the terms of the Eye-Net Mobile investments (March and December 2025), specifically the antidilution protections and warrant exercise prices, which may impact future dilution.
- Geopolitical Exposure: Monitor the impact of regional conflicts on the Company's Israeli workforce and supply chain continuity.
- Grant Obligations: Assess the potential liability for royalties owed to the Israel Innovation Authority (IIA) upon future commercialization of grant-funded technology.